Legal Newsline

Wednesday, April 1, 2020

Having a drug that cost $50K per dose hurt sales, says class action suit by investor

Federal Court

By David Beasley | Mar 18, 2020

Andexxa box mobile

SAN FRANCISCO (Legal Newsline) - Portola Pharmaceuticals Inc. misled investors by exaggerating the potential of a new drug, a class action lawsuit contends.

Portola called Andexxa, used as an antidote to anticoagulation drugs, “one of the most successful drug launches in history” the lawsuit by the Southeast Pennsylvania Transportation Authority said. The company in August 2019 had a stock offering, raising $250 million for the company, according to the suit.

 “Portola’s materially false and misleading statements and omissions inflated the price of Portola stock,” the complaint alleges.

 The wholesale price of nearly $50,000 per dose, dampened sales, the suit said. “The company knowingly concealed from investors that the ‘strong demand’ for Andexxa simply did not exist,” it says. 

The securities suit, on behalf of those who purchased shares of Portola’s common stock from Jan. 8, 2019, to Feb. 26, 2020, seeks unspecified monetary damages plus attorney fees.

Southeastern Pennsylvania Transportation Authority v. Portola Pharmaceuticals, Inc. U.S. District Court, Northern District of California. 3:20-CV-01501

Want to get notified whenever we write about U.S. District Court for the Northern District of California ?

Sign-up Next time we write about U.S. District Court for the Northern District of California, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.

Organizations in this Story

U.S. District Court for the Northern District of California